Antibody to the Hepatitis C Virus in Acute Hepatitis and Chronic Liver Diseases in Japan
Overview
Affiliations
In a 6-month follow-up study of acute hepatitis in Japan, 31 out of 41 (75.6%) cases of post-transfusion non-A and non-B hepatitis (NANB-PTH) and 14 out of 40 (35.0%) cases of sporadic non-A non-B hepatitis (NANB-SPO) were found to be positive for antibody to the hepatitis C virus (HCVAb). After 12 months of follow-up, 30 cases (81.1%) became chronic among 37 HCVAb positive acute NANB hepatitis cases. This figure shows a significantly higher rate of chronicity as compared with HCVAb negative acute NANB hepatitis. The prevalences of HCVAb in hepatitis B surface antigen (HBsAg) negative cases of chronic hepatitis and liver cirrhosis were 76.3% (200/262) and 66.7% (106/159), respectively, which were significantly different from the values of 5.1% (13/255) and 10.6% (13/123) observed in HBsAg positive cases. Of chronic liver disease cases positive for HCVAb, 45.8% (152/332) had a history of blood transfusion, in contrast to the value of 3.7% (13/352) observed in HBsAg positive cases of chronic liver disease that were negative for HCVAb.
Anagaw B, Shiferaw Y, Anagaw B, Belyhun Y, Erku W, Biadgelegn F BMC Res Notes. 2012; 5:55.
PMID: 22264306 PMC: 3274440. DOI: 10.1186/1756-0500-5-55.
Kubo N, Furusyo N, Nakashima H, Kashiwagi K, Hayashi J Eur J Epidemiol. 2005; 20(3):251-61.
PMID: 15921043 DOI: 10.1007/s10654-004-6516-5.
Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.
Tillmann H, Chen D, Trautwein C, Kliem V, Grundey A, Boker K Gut. 2001; 48(5):714-8.
PMID: 11302974 PMC: 1728277. DOI: 10.1136/gut.48.5.714.
Toyoda H, Fukuda Y, Hayakawa T, Kumada T, Nakano S, Takamatsu J Dig Dis Sci. 1999; 44(10):1944-9.
PMID: 10548340 DOI: 10.1023/a:1026693512265.
Fabris P, Infantolino D, Biasin M, Marchelle G, Venza E, Marin V Infection. 1999; 27(2):86-91.
PMID: 10219636 DOI: 10.1007/BF02560503.